Tessellate BIO, an Emerging Precision Oncology Company Announces the Appointment of World-Leading Scientists to its Scientific Advisory Board

Amsterdam, the Netherlands and London, UK – 15 November 2023 – Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, today announces the appointment of multiple international experts to its Scientific Advisory Board. A key part of Tessellate BIO’s strategy is to source cutting-edge research from international world-renowned laboratories to […]

Tessellate BIO Emerges from Stealth

The Next Generation Synthetic Lethality Precision Oncology Company The company aims to become a global leader in precision oncology by redefining Synthetic Lethality to treat large, currently unserved patient populations Lead program targets Alternative Lengthening of Telomeres (ALT) through the FANCM protein complex Company backed by leading venture firms, BioGeneration Ventures (BGV) and Forbion World-class […]